Robert B. Den, MD
Room G-301, Bodine Center
Philadelphia, PA 19107
(215) 955-0412 fax
Most Recent Peer-reviewed Publications
- MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2
- RB loss promotes prostate cancer metastasis
- Prognostic outlier genes for enhanced prostate cancer treatment
- Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer
- Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality
Harvard Medical School, Boston, MA
Radiation Oncology, Thomas Jefferson University, Philadelphia, PA
Associate Professor, Department of Cancer Biology
Research and Clinical Interests
I am a board-certified radiation oncologist who specializes in the treatment of prostate cancer. I see patients and discuss their cases in a genitourinary multidisciplinary clinic with colleagues in urology and medical oncology. I specialize in using IMRT to treat men with prostate cancer to improve patients outcomes and decrease the side effects of treatment.
I am also a translational researcher with a laboratory at Jefferson that focuses on combining new biologic agents with radiation therapy. The goal of this work is to introduce the most exciting compounds into clinical trials to benefit my patients.